Ghost Tree Partners Outperforms With These Biotech ShortsRupert Hargreaves
Ghost Tree Partners, the biotech-focused hedge fund, returned -8.6% in March, outperforming the broader market but underperforming the rest of the hedge fund industry.
The HFRI Fund Weighted Composite index fell 8.3% during the first three months of the year.
For more up-to-date hedge fund content, and exclusive access to value-focused hedge fund managers, check out Hidden Value Stocks.
According to the firm's first-quarter letter to investors, Ghost Tree spent much of the second half of the first quarter "making . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email firstname.lastname@example.org or click chat